3D bioprinting for drug discovery and development in pharmaceutics


PENG W., DATTA P., AYAN B., Ozbolat V. , SOSNOSKI D., OZBOLAT I. T.

ACTA BIOMATERIALIA, cilt.57, ss.26-46, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 57
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.actbio.2017.05.025
  • Dergi Adı: ACTA BIOMATERIALIA
  • Sayfa Sayıları: ss.26-46

Özet

Successful launch of a commercial drug requires significant investment of time and financial resources wherein late-stage failures become a reason for catastrophic failures in drug discovery. This calls for infusing constant innovations in technologies, which can give reliable prediction of efficacy, and more importantly, toxicology of the compound early in the drug discovery process before clinical trials. Though computational advances have resulted in more rationale in silico designing, in vitro experimental studies still require gaining industry confidence and improving in vitro-in vivo correlations. In this quest, due to their ability to mimic the spatial and chemical attributes of native tissues, three-dimensional (3D) tissue models have now proven to provide better results for drug screening compared to traditional two-dimensional (2D) models. However, in vitro fabrication of living tissues has remained a bottleneck in realizing the full potential of 3D models. Recent advances in bioprinting provide a valuable tool to fabricate biomimetic constructs, which can be applied in different stages of drug discovery research. This paper presents the first comprehensive review of bioprinting techniques applied for fabrication of 3D tissue models for pharmaceutical studies. A comparative evaluation of different bioprinting modalities is performed to assess the performance and ability of fabricating 3D tissue models for pharmaceutical use as the critical selection of bioprinting modalities indeed plays a crucial role in efficacy and toxicology testing of drugs and accelerates the drug development cycle. In addition, limitations with current tissue models are discussed thoroughly and future prospects of the role of bioprinting in pharmaceutics are provided to the reader.